Imara, Inc.
(NASDAQ : IMRA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -4.22%50.560.9%$1775.43m
JNJJohnson & Johnson -2.86%160.160.7%$974.67m
ABBVAbbVie, Inc. -1.39%130.141.9%$882.99m
MRKMerck & Co., Inc. -2.80%77.740.7%$847.60m
BMYBristol-Myers Squibb Co. -2.63%61.871.0%$648.56m
LLYEli Lilly & Co. -2.65%236.621.1%$602.80m
AZNAstraZeneca Plc -4.77%56.281.0%$226.50m
NVSNovartis AG -3.31%84.150.2%$185.13m
GSKGlaxoSmithKline Plc -2.59%43.930.2%$166.70m
NVONovo Nordisk A/S -1.41%94.020.1%$145.03m
VTRSViatris, Inc. -2.37%14.190.0%$133.60m
RGENRepligen Corp. 1.40%186.386.7%$100.35m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 6.00%116.680.0%$78.15m
IMMXImmix Biopharma, Inc. -8.02%4.150.0%$65.44m
SNYSanofi -1.50%50.470.2%$64.55m

Company Profile

Imara, Inc. is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Boston, MA.